GRAIL to Present at the 44th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

GRAIL (Nasdaq: GRAL) announced management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, Jan. 12, 2026 at 7:30 a.m. PT. Live and replay webcasts will be available in the investor relations section at investors.grail.com. The webcast will be archived and available for replay for at least 30 days after the event.

Key Figures

Conference edition 44th 44th Annual J.P. Morgan Healthcare Conference

Presentation time 7:30 a.m. PT Scheduled presentation on Monday, Jan. 12

Webcast archive period 30 days Replay available for at least 30 days after event

Market Reality Check

$91.09 Last Close

Volume Volume 890,422 is at 0.76x the 20-day average of 1,174,015, indicating quieter trading ahead of the event. normal

Technical Shares at $90.82 are trading above the 200-day MA of $49.18, despite a -4.46% move over the last 24 hours.

Peers on Argus

GRAL was down -4.46% while peers showed mixed performance: NEOG -2.83%, TWST -3.7%, OPK -0.72%, NEO 0%, and CDNA +3.26%, suggesting stock-specific factors rather than a unified sector move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 01	Inducement grants	Neutral	-0.9%	Inducement RSU grants to 21 non-executive employees totaling 21,570 shares.
Nov 18	Conference appearance	Neutral	-4.1%	Announcement of management presentation at Piper Sandler healthcare conference.
Nov 12	Earnings results	Positive	+1.6%	Q3 2025 revenue growth, narrowed losses, financings, and extended cash runway.
Nov 04	Conference appearance	Neutral	+4.9%	Management presentation at Wolfe Research healthcare conference with webcast access.
Oct 29	Earnings date notice	Neutral	-1.3%	Scheduled Q3 2025 results release and Analyst Day webcast details.

Pattern Detected

Recent conference appearance announcements for GRAL have typically seen modest single-digit share moves, while earnings-related releases have aligned positively with fundamental improvements.

Recent Company History

Over the last few months, GRAIL has mixed routine corporate updates with key financial milestones. An inducement grant on Dec 1, 2025 and multiple conference appearance notices (Piper Sandler, Wolfe Research) saw modest, generally small share moves. In contrast, Q3 2025 earnings on Nov 12, 2025 highlighted revenue growth to $36.2M, improved gross profit, significant financings (~$325M private placement and a planned $110M Samsung investment), and an extended cash runway. Today’s J.P. Morgan conference appearance continues the pattern of investor-relations visibility rather than a new fundamental shift.

Market Pulse Summary

This announcement detailed GRAIL’s participation in the 44th Annual J.P. Morgan Healthcare Conference on Jan. 12 at 7:30 a.m. PT, with a live and replay webcast available for at least 30 days. Within recent context, GRAIL has combined conference visibility with solid Q3 2025 revenue growth and strengthened liquidity through capital raises. Investors monitoring the story may focus on how management’s presentation frames growth, commercialization, and prior financing activities.

AI-generated analysis. Not financial advice.

MENLO PARK, Calif., Dec. 15, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, Jan. 12 at 7:30 a.m. PT. 

Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.

About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.

For more information, visit grail.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302642502.html

SOURCE GRAIL, Inc.

FAQ

When will GRAIL (GRAL) present at the J.P. Morgan Healthcare Conference?

GRAIL management will present on Monday, Jan. 12, 2026 at 7:30 a.m. PT.

How can investors watch the GRAIL (GRAL) presentation on Jan. 12, 2026?

Investors can watch the live webcast or replay via the investor relations site at investors.grail.com.

Will the GRAIL (GRAL) webcast be available after the conference?

Yes. The webcast will be archived and available for replay for at least 30 days after the event.

Where is the 44th Annual J.P. Morgan Healthcare Conference taking place for the GRAIL presentation?

The conference presentation takes place in San Francisco as part of the J.P. Morgan Healthcare Conference.

What topics will GRAIL (GRAL) management cover in the Jan. 12 presentation?

The announcement states management will present company developments and outlook; specific topics were not listed.

Is registration required to view GRAIL (GRAL) webcast at investors.grail.com?

The announcement directs viewers to the investor relations site for live and replay webcasts; registration details are available on that site.